Media coverage about Cytori Therapeutics (NASDAQ:CYTX) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cytori Therapeutics earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.7079381102724 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- Stock’s Technical Levels Evaluation: Cytori Therapeutics, Inc. (NASDAQ: CYTX) – The Investor Guide (wallstreetnews24.com)
- Eye-Catching Shares: Cytori Therapeutics Inc (NASDAQ: CYTX) – Alpha Beta Stock (alphabetastock.com)
- Stock’s Risk Factors in the Spotlight: Cytori Therapeutics, Inc., (NASDAQ: CYTX) – Stock Watch (stocksnewstimes.com)
- Signals from Technical Perspective: Cytori Therapeutics, Inc. (NASDAQ: CYTX) – The Investor Guide (wallstreetnews24.com)
- Cytori Therapeutics Inc (NASDAQ:CYTX) Closed 44.8% Above Its 50 Day Average – First News 24 (firstnewspaper24.com)
Cytori Therapeutics (NASDAQ CYTX) traded down 0.458% during midday trading on Tuesday, reaching $0.456. The company had a trading volume of 183,595 shares. The firm has a 50-day moving average price of $0.40 and a 200-day moving average price of $0.79. Cytori Therapeutics has a 52 week low of $0.28 and a 52 week high of $2.13. The company’s market capitalization is $15.83 million.
Cytori Therapeutics (NASDAQ:CYTX) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.02). Cytori Therapeutics had a negative return on equity of 202.62% and a negative net margin of 450.34%. The business had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.23 million. During the same quarter last year, the company earned ($0.43) earnings per share. Cytori Therapeutics’s quarterly revenue was down 18.2% compared to the same quarter last year. Analysts expect that Cytori Therapeutics will post ($0.60) EPS for the current fiscal year.
Several equities analysts have recently weighed in on the company. B. Riley reiterated a “neutral” rating on shares of Cytori Therapeutics in a research report on Friday, August 11th. ValuEngine upgraded Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 13th. Maxim Group set a $5.00 price target on Cytori Therapeutics and gave the company a “buy” rating in a research report on Friday, August 11th. Finally, Zacks Investment Research cut Cytori Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.